Company Announcements

Transaction in Own Shares

Source: RNS
RNS Number : 0157Q
22 October 2021


BAE Systems plc  





BAE Systems plc (the "Company") announces that, in accordance with the terms of its share repurchase programme announced on 29 July 2021, the Company purchased the following number of its ordinary shares of 2.5p each from Morgan Stanley & Co. International plc. Such purchase was effected pursuant to instructions issued by BAE Systems plc on 29 July 2021.


Date of purchase:

22nd October 2021

Number of ordinary shares purchased:


Highest price paid per share (pence):


Lowest price paid per share (pence):


Volume weighted average price paid per share (pence):




The Company intends to cancel the purchased shares.

Since 29 July 2021, BAE Systems plc has purchased 43,956,458 shares at a cost (including dealing and associated costs) of £251,668,875.32.


A full breakdown of the individual trades made by Morgan Stanley & Co. International plc on behalf of the Company as part of the share repurchase programme is attached to this document.


[RNS team to upload attachment]


This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.


This announcement will also be available on the Company's website at: 


For further information, please contact:



Martin Cooper,

Investor Relations Director

Telephone: +44 (0)1252 383455


Kristina Anderson,

Director, Media Relations

Telephone: +44 (0) 7540 628673










This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.